BioPharma Dive - Latest News

Regeneron makes obesity push; Atai, Alto ink brain drug deals

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Jun 4, 2025 - 14:55
 0
Regeneron makes obesity push; Atai, Alto ink brain drug deals

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Read More

Tags:

Previous Article

Bayer's Vividion secures rights to world's only clinical-stage WRN inhibitor fro...

Next Article

After groundbreaking CRISPR therapy, a homecoming

Related Posts

FDA to use new review tool on Sarepta’s gene therapy work

FDA to use new review tool on Sarepta’s gene therapy work

Jun 4, 2025  0

HHS terminates Moderna contract to develop bird flu vaccine

HHS terminates Moderna contract to develop bird flu vac...

May 29, 2025  0

Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC

Keros lays off nearly half its staff; Astellas buys int...

May 30, 2025  0